SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. (SLS): 4 pipeline candidates · 1 upcoming catalyst · ~37 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
36.8 months
D/E 0.06 · 0% dilution
Lead: Phase 3
4 candidates
1 upcoming, next in ~166d
N/A
A transparent, data-derived signal for SELLAS Life Sciences Group, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.5B
Cash
$107.2M
Quarterly Burn
$8.8M
Runway
36.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| galinpepimut-s | Phase 3 |
| gm-csf | Phase 3 |
| gps+ | Phase 3 |
| sls009 | Phase 1/Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
164
Total value held
$323.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 15,051,858 | $63.7M |
| blackrock, inc. | 12,198,410 | $51.6M |
| susquehanna international group, llp | 8,981,556 | $38.0M |
| state street corp | 8,396,356 | $35.5M |
| citadel advisors llc | 4,882,641 | $20.7M |
| geode capital management, llc | 3,912,606 | $16.6M |
| marshall wace, llp | 2,037,162 | $8.6M |
| jones financial companies lllp | 1,675,077 | $7.3M |
| vanguard portfolio management llc | 1,462,806 | $6.2M |
| morgan stanley | 1,336,293 | $5.7M |
Showing top 10 of 164 institutional holders of SELLAS Life Sciences Group, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in SELLAS Life Sciences Group, Inc.'s pipeline?
SELLAS Life Sciences Group, Inc. (SLS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is SELLAS Life Sciences Group, Inc.'s lead drug candidate?
SELLAS Life Sciences Group, Inc.'s most advanced tracked candidate is galinpepimut-s (Phase 3) for Acute Myeloid Leukemia.
What is SELLAS Life Sciences Group, Inc.'s next catalyst?
SELLAS Life Sciences Group, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monoth" — expected December 1, 2026.
What is SELLAS Life Sciences Group, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, SELLAS Life Sciences Group, Inc. has approximately 36.8 months of cash runway.
What is SELLAS Life Sciences Group, Inc.'s market capitalization?
SELLAS Life Sciences Group, Inc.'s market capitalization is approximately $1.5B.
Get the full picture on SELLAS Life Sciences Group, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.